JonesTrading analyst Debanjana Chatterjee has maintained their bullish stance on TVRD stock, giving a Buy rating on August 22.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Debanjana Chatterjee has given her Buy rating due to a combination of factors related to Tvardi Therapeutics’ promising drug development pipeline. The upcoming Phase 2 REVERT trial results for TTI-101, expected in the fourth quarter of 2025, are anticipated to demonstrate a competitive profile, which could serve as a significant catalyst for the company’s stock.
The base case scenario suggests that TTI-101 could achieve stabilization in forced vital capacity (FVC) for patients, a notable achievement for a novel idiopathic pulmonary fibrosis (IPF) treatment. This stabilization is projected to outperform the placebo arm, which is expected to show a decline in FVC. Such positive outcomes could potentially lead to a substantial increase in Tvardi Therapeutics’ stock value, enhancing its attractiveness to investors.
In another report released on August 22, Raymond James also maintained a Buy rating on the stock with a $62.00 price target.